ImmunoGen, Inc.
IMGNDrugs in Pipeline
15
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
Single high dose of liposomal amphotericin B
Disseminated Histoplasma Capsulatum Infection
Pegylated Liposomal Doxorubicin
Epithelial Ovarian Cancer
Mirvetuximab Soravtansine
Epithelial Ovarian Cancer
Vacc-4x
HIV-1 Infection
Sterile water
HIV I Infection
IMGN853
Endometrial Cancer
SARS-CoV-2 DNA Vaccine (ICCOV)
COVID-19
Romidepsin
HIV I Infection
Vacc-C5/GM-CSF
HIV-1 Infection
Lorvotuzumab Mertansine (IMGN901)
Leukemia
GP2 peptide + GM-CSF vaccine
Breast Cancer
Vacc-4x low dose
HIV Infection
rhuGM-CSF
HIV-1 Infection
IMGC936
Advanced Solid Tumor
BB-10901
Small Cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Single high dose of liposomal amphotericin B | Phase 3 | Disseminated Histoplasma Capsulatum Infection | - | - |
Pegylated Liposomal Doxorubicin | Phase 3 | Epithelial Ovarian Cancer | - | - |
Mirvetuximab Soravtansine | Phase 3 | Epithelial Ovarian Cancer | - | - |
Vacc-4x | Phase 2 | HIV-1 Infection | - | - |
Sterile water | Phase 2 | HIV I Infection | - | - |
IMGN853 | Phase 2 | Endometrial Cancer | - | - |
SARS-CoV-2 DNA Vaccine (ICCOV) | Phase 2 | COVID-19 | - | - |
Romidepsin | Phase 2 | HIV I Infection | - | - |
Vacc-C5/GM-CSF | Phase 2 | HIV-1 Infection | - | - |
Lorvotuzumab Mertansine (IMGN901) | Phase 2 | Leukemia | - | - |
GP2 peptide + GM-CSF vaccine | Phase 2 | Breast Cancer | - | - |
Vacc-4x low dose | Phase 2 | HIV Infection | - | - |
rhuGM-CSF | Phase 2 | HIV-1 Infection | - | - |
IMGC936 | Phase 2 | Advanced Solid Tumor | - | - |
BB-10901 | Phase 2 | Small Cell Lung Cancer | - | - |
Epithelial Ovarian Cancer
2 drugs in this indication
Small Cell Lung Cancer
1 drug in this indication
Advanced Solid Tumor
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in ImmunoGen, Inc.'s drug pipeline?→
CatalystAlert tracks 15 drug candidates in ImmunoGen, Inc.'s (IMGN) pipeline across Phase 3, Phase 2. Its lead program is Single high dose of liposomal amphotericin B (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ImmunoGen, Inc.'s next FDA catalyst?→
ImmunoGen, Inc.'s (IMGN) next tracked catalyst is a Phase 2 expected October 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IMGN biotech catalysts?→
Add IMGN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ImmunoGen, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.